Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Myasthenia gravis

¹Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK.

Current Opinion in Immunology

|December 1, 1993

Summary

The cause of myasthenia gravis autoantibodies targeting acetylcholine receptors remains unclear, potentially involving the thymus and cross-reacting epitopes. Researchers aim to develop targeted therapies to inhibit this autoimmune response in patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Forbidden clones.

Immunology today·2014

Same author

Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood.

Journal of clinical immunology·2013

Same author

Anti-cytokine autoantibodies suggest pathogenetic links with autoimmune regulator deficiency in humans and mice.

Clinical and experimental immunology·2013

Same author

Thymoma and paraneoplastic myasthenia gravis.

Autoimmunity·2010

Same author

Expanded TCR Vbeta subsets of CD8(+) T-cells in late-onset myasthenia gravis: novel parallels with thymoma patients.

Journal of neuroimmunology·2009

Same author

Hypothetical review: thymic aberrations and type-I interferons; attempts to deduce autoimmunizing mechanisms from unexpected clues in monogenic and paraneoplastic syndromes.

Clinical and experimental immunology·2008

Area of Science:

Immunology
Neurology
Oncology

Background:

Myasthenia gravis is an autoimmune disorder characterized by autoantibodies against the muscle acetylcholine receptor.
The thymus gland and its epithelial tumors are implicated in the pathogenesis of myasthenia gravis.
Cross-reacting epitopes may play a role in initiating or perpetuating the autoimmune response.

Purpose of the Study:

To elucidate the underlying causes of the pathogenic autoantibody response in myasthenia gravis.
To investigate the role of the thymus and thymic epithelial tumors in the development of myasthenia gravis.
To explore potential strategies for selectively inhibiting the autoimmune response in myasthenia gravis patients.

Main Methods:

Review of existing literature on myasthenia gravis pathogenesis.
Analysis of immunological mechanisms involving the thymus and acetylcholine receptors.
Exploration of epitope-based theories and potential therapeutic targets.

Main Results:

The precise trigger for autoantibody production against acetylcholine receptors is complex and not fully understood.
Evidence suggests a significant involvement of the thymus, including thymic epithelial tumors, in the autoimmune process.
Cross-reacting epitopes are hypothesized to contribute to the initiation and maintenance of the autoimmune response.

Conclusions:

Understanding the intricate relationship between the thymus and autoimmunity is crucial for myasthenia gravis research.
Developing targeted therapies to selectively inhibit the pathogenic autoantibody response is a key challenge.
Further research into epitope mimicry and thymic pathology may reveal novel therapeutic avenues for myasthenia gravis.

Related Experiment Videos